D.W. Miles

2.3k total citations
55 papers, 1.8k citations indexed

About

D.W. Miles is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, D.W. Miles has authored 55 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 13 papers in Molecular Biology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in D.W. Miles's work include Cancer Treatment and Pharmacology (23 papers), HER2/EGFR in Cancer Research (12 papers) and Immunotherapy and Immune Responses (8 papers). D.W. Miles is often cited by papers focused on Cancer Treatment and Pharmacology (23 papers), HER2/EGFR in Cancer Research (12 papers) and Immunotherapy and Immune Responses (8 papers). D.W. Miles collaborates with scholars based in United Kingdom, France and Spain. D.W. Miles's co-authors include L. G. Bobrow, B Davies, RD Rubens, Frances R. Balkwill, R.D. Rubens, Javier Cortés, Joyce Taylor‐Papadimitriou, Véronique Dièras, Jingbo Yi and Xavier Pivot and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

D.W. Miles

54 papers receiving 1.7k citations

Peers

Countries citing papers authored by D.W. Miles

Since Specialization

Citations

This map shows the geographic impact of D.W. Miles's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D.W. Miles with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D.W. Miles more than expected).

Fields of papers citing papers by D.W. Miles

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D.W. Miles. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D.W. Miles. The network helps show where D.W. Miles may publish in the future.

Co-authorship network of co-authors of D.W. Miles

This figure shows the co-authorship network connecting the top 25 collaborators of D.W. Miles. A scholar is included among the top collaborators of D.W. Miles based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D.W. Miles. D.W. Miles is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LBA11 Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer 2021 ·Annals of Oncology ·Helena Earl, Louise Hiller, Julie Dunn, Pierfranco Conté, Roberto D’Amico, Valentina Guarneri, Heikki Joensuu, Teppo Huttunen, (unknown), James Abraham, David Cameron, D.W. Miles, Andrew Wardley, Gilles Romieu, M. Debled, (unknown), Henrik Lindman, Judith Fraser, (unknown), Xavier Pivot	14
2	LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC) 2020 ·Annals of Oncology ·D.W. Miles, Joseph Gligorov, Fabrice André, David Cameron, Andreas Schneeweiß, C.H. Barrios, Binghe Xu, Andrew Wardley, Diego Kaen, Livia Andrade, Semiglazov Vf, Mattea Reinisch, Monika Patre, L. Morales, Kenneth Russell, Margarita Donica, Joyce O’Shaughnessy	74
3	288P Final results from PERUSE, a global study of pertuzumab (P), trastuzumab (H) and investigator’s chosen taxane as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC) 2020 ·Annals of Oncology ·D.W. Miles, Eva Ciruelos, Andreas Schneeweiß, Fabio Puglisi, (unknown), Mario Campone, Igor Bondarenko, Zbigniew Nowecki, Hassan Errihani, Shani Paluch–Shimon, Andrew Wardley, (unknown), (unknown), Dirk Klingbiel, (unknown), Thomas Bachelot	2
4	First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients 2013 ·Annals of Oncology ·D.W. Miles, Véronique Dièras, Javier Cortés, (unknown), Jingbo Yi, Joyce O’Shaughnessy	159
5	Genetic Markers in Relation to Bevacizumab-induced Hypertension 2011 ·European Journal of Cancer ·Diether Lambrechts, D.W. Miles, (unknown), Leonard B. Saltz, B. Escudier, Eric Van Cutsem, Aruna T. Bansal, (unknown), Peter Carmeliet, Sanne de Haas	1
6	Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer 2011 ·Annals of Oncology ·Aman U. Buzdar, Binghe Xu, Raghunadharao Digumarti, L. Goedhals, (unknown), Semiglazov Vf, Sergey Cheporov, (unknown), Silke Hoersch, Karen Rittweger, D.W. Miles, J. O’Shaughnessy, Sergei Tjulandin	11
7	13. NEW BIOLOGICAL THERAPIES FOR BREAST CANCER 2002 ·International Journal of Clinical Practice ·(unknown), D.W. Miles	9
8	Metastatic eccrine porocarcinoma: Response to docetaxel (Taxotere) chemotherapy 2001 ·Annals of Oncology ·T.A. Plunkett, A M Hanby, D.W. Miles, R.D. Rubens	47
9	A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer 2001 ·European Journal of Cancer ·D.W. Miles, Ian E. Smith, Robert E. Coleman, A H Calvert, Michael Lind	57
10	Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. 1999 ·PubMed ·Mitch Dowsett, C. Pfister, (unknown), D.W. Miles, Stephen Houston, J. Arnold Verbeek, Holly Gundacker, A. Sioufi, I E Smith	70
11	Immunotherapy: the last 25 years 1999 ·Cancer Treatment Reviews ·T.A. Plunkett, D.W. Miles	0
12	Therapeutic Aspects of Polymorphic Epithelial Mucin in Adenocarcinoma 1999 ·Pharmacology & Therapeutics ·D.W. Miles, Joyce Taylor‐Papadimitriou	31
13	Immunotherapy and breast cancer 1998 ·Cancer Treatment Reviews ·T.A. Plunkett, D.W. Miles	2
14	A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer 1996 ·British Journal of Cancer ·D.W. Miles, (unknown), Rosalind Graham, (unknown), (unknown), Joyce Taylor‐Papadimitriou, RD Rubens	92
15	Transverse Leukonychia 1995 ·New England Journal of Medicine ·D.W. Miles, R.D. Rubens	5
16	Expression of sialyl-Tn in gastric cancer: correlation with known prognostic factors 1995 ·British Journal of Cancer ·D.W. Miles, Jacqueline M. Linehan, Paul J. Smith, (unknown)	36
17	Expression of sialyl-Tn predicts the effect of adjuvant chemotherapy in node-positive breast cancer 1994 ·British Journal of Cancer ·D.W. Miles, Lisa Happerfield, Paul Smith, (unknown), L. G. Bobrow, W. Gregory, R.D. Rubens	67
18	High-dose epirubicin as primary chemotherapy in advanced breast carcinoma: a phase II study 1991 ·Cancer Chemotherapy and Pharmacology ·(unknown), (unknown), D.W. Miles, (unknown), Martin Richards, R.D. Rubens	27
19	Plasma C‐peptide Levels Identify Insulin‐treated Diabetic Patients Suitable for Oral Hypoglycaemic Therapy 1984 ·Diabetic Medicine ·P. J. Grant, (unknown), D.W. Miles	10
20	Galvanic stimulation of the tongue as a prognostic index in Bell's palsy. 1965 ·BMJ ·O. A. Peiris, D.W. Miles	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact